Director Dealings
05/12/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221205:nRSE5208Ia&default-theme=true
RNS Number : 5208I Ergomed plc 05 December 2022
Director Dealing
Guildford, UK - 5 December 2022: Ergomed plc (LSE: ERGO) ("Ergomed" or the
"Company"), a company focused on providing specialised services to the
pharmaceutical industry, announces that on 2 December 2022, Richard Barfield,
Chief Financial Officer of Ergomed, exercised options under the Company's Long
Term Incentive Plan and sold the shares issued by the Company pursuant to such
exercise. Mr Barfield exercised options over 125,000 ordinary shares of £0.01
each in the Company ("Ordinary Shares") at an exercise price of £0.01 per
share and subsequently sold 125,000 Ordinary Shares at a price
of £13.45 per share.
Following this sale, Richard Barfield holds 25,000 Ordinary Shares
representing 0.05% of the Company's issued share capital.
The notification set out below is provided in accordance with the requirements
of Article 19 of the UK Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Richard Barfield
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Ergomed plc
b) Legal Entity Identifier 213800BVS8I9VMC1AP84
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 1 pence each
Identification code
GB00BN7ZCY67
b) Nature of the transaction Exercise of share options under the Company's Long Term Incentive Plan
c) Currency GBP
d) Price(s) and volume(s) Price(s) Volume(s)
Exercise price £0.01 125,000
e) Aggregated information
- Aggregated volume
- Price n/a
- Aggregated total
f) Date of the transaction 2 December 2022
g) Place of the transaction London Stock Exchange, AIM
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Richard Barfield
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Ergomed plc
b) Legal Entity Identifier 213800BVS8I9VMC1AP84
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 1 pence each
Identification code
GB00BN7ZCY67
b) Nature of the transaction Sale
c) Currency GBP
d) Price(s) and volume(s) Price(s) Volume(s)
£13.45 125,000
e) Aggregated information
- Aggregated volume
125,000
- Price £13.45
£1,681,250
- Aggregated total
f) Date of the transaction 2 December 2022
g) Place of the transaction London Stock Exchange, AIM
ENDS
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 402 975
Dr Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets & Strategy)
Numis
Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP
Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Consilium Strategic
Communications
Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal
ergomed@consilium-comms.com
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHUPGPPPUPPGBC